

# October 24, 2023

Analysts

Matt Bryson
(617) 695-6302
matthew.bryson@wedbush.com

# **Hardware**

# **Daily Views on Tech Headlines**

NVDA, AMD, INTC, ARM, TSM: NVDA and AMD working on Arm based CPUs for PCs

<u>View</u>: Reuters yesterday reported that NVDA is working on Arm based CPUs that would power Windows based PCs. The new parts could be available for sale as soon as 2025. In addition, Reuters reported AMD has a similar effort underway, in-line with a SemiAccurate report from earlier this year.

QCOM has been working on Arm based parts with MSFT support for some time (it's likely we get an update on this effort this week during QCOM's Snapdragon Summit, which starts today) albeit with limited success. Having said this, AAPL with its M-Series processors has proven Arm processors are more than capable of providing robust PC performance, illustrating the potential Arm could have in a Windows based environment.

Net, we see this news as a potential concern for INTC, though we continue to believe that INTC's forward results will be predominantly dictated by the company's ability to execute to its manufacturing roadmap (which will determine the future competitiveness of its product portfolio). We see modest positive implications for NVDA (the PC opportunity is relatively modest compared with revenue and margin tied to AI) from this new opportunity and limited impact for AMD (it continues to maintain a more modest share in PCs that could be bolstered by a successful Arm initiative). Rather, the larger/more likely positive implications might be for Arm (given the potential TAM expansion should Arm compute further penetrate the PC market) and TSMC (which would likely fab any INTC alternatives, should QCOM, NVDA, or AMD prove successful with their initiatives). Reuters

YMTC, NAND: YMTC develops 120 layer NAND; NAND conditions improve

<u>View</u>: DigiTimes suggests that YMTC has developed a 120 layer NAND part that both skirts US restrictions (geared towards 128 layer parts) and improves I/O performance. The new parts are expected to ship in 2024. While we see this advance as offering YMTC a near to intermediate term means of remaining competitive with foreign parts. However, we also believe YMTC will struggle to keep innovating without access to more advanced tools moving forward, limiting its ability to impact the broader market.

And shifting to the broader market, DigiTimes notes that a focus by fabs on profitability is continuing to bolster pricing with 512 Gb parts not available in China below \$2.20. We'd note this commentary fits with data from China Flash Market suggesting that spot pricing continues to lift, with the Chinese price tracker now indicating 512 Gb chips are being priced at \$2.10, up 10 cents this week and 50% above the midyear lows of ~\$1.40. DigiTimes, DigiTimes, China Flash MarketAAPL, NVDA: Apple AI investment

<u>View</u>: Bloomberg this weekend suggests that Apple was caught flatfooted by the sudden emergence of generative AI and will invest \$1B in 2024 to try and catch up to peers. Numerous articles are out today quoting a competitor suggesting Apple's spend will be nearly 5X this amount (likely purchasing NVDA based servers) and

Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–4 of this report for analyst certification and important disclosure information.



that even that amount will leave Apple lagging its peers.

We don't have insight into Apple's spending plans, but would note that spending levels will very much depend on whether Apple is planning to use internal compute resources as well as an internally trained generative AI model. And regardless of the capex intensity involved in Apple's plans, we see reports around its need to lift spending as generally positive for the AI complex (and likely NVDA) given any increase in spend will necessarily eventually flow through into increased hardware requirements. Bloomberg, wccftech

Smartphones: Demand for high-end handsets recovering?

<u>View</u>: High-end phone lenses manufacturers Largan Precision and GSEO are seeing better demand for premium smartphones that are exceeding expectations. According to DigiTimes, Largan is seeing an increase in orders through November (driven by a US client), while GSEO has seen substantial revenue growth in the 2H'23 and expects double-digit Y/Y revenue growth for 2023.

We have seen some indications of modest improvement in consumer related hardware builds/ spend. This report fits with those recent checks. While we see any pickup as somewhat limited in scale and potentially threatened by macro events, we still see momentum as positive for the broader semiconductor complex (with soft demand and inventory reductions in this space having weighed heavily on industry dynamics for some time). DigiTimes



#### Risks to the Attainment of Our Price Targets and Ratings: Hardware

Shifts in competition, pricing, technology, and macroeconomic conditions.

Changes in hyperscale spending tied to shifts in growth or increased optimization.

Unforeseen events affecting production capacity (power outages, fires, storms, etc.)

Shifts in worldwide trade conditions that lead to macro instability and or close certain markets.

Increased competition from China based manufacturers entering new markets.

#### **Analyst Certification**

I, Matt Bryson, certifies that the views expressed in this report accurately reflect my personal opinion and that I have not and will not, directly or indirectly, receive compensation or other payments in connection with my specific recommendations or views contained in this report.

#### **Mentioned Companies**

Company	Rating	Price	Target
Apple	OUTPERFORM	\$173.93	\$240.00
Advanced Micro Devices Inc	OUTPERFORM	\$117.60	\$155.00
Intel Corp	NEUTRAL	\$35.69	\$35.00
Microsoft	OUTPERFORM	\$320.77	\$400.00
Nvidia	OUTPERFORM	\$471.16	\$600.00
Taiwan Semiconductor	OUTPERFORM	TWD547.00	TWD700.00

#### **Investment Rating System:**

OUTPERFORM: Expect the total return of the stock to outperform relative to the median total return of the analyst's (or the analyst's team) coverage universe over the next 6-12 months.

NEUTRAL: Expect the total return of the stock to perform in-line with the median total return of the analyst's (or the analyst's team) coverage universe over the next 6-12 months.

UNDERPERFORM: Expect the total return of the stock to underperform relative to the median total return of the analyst's (or the analyst's team) coverage universe of the next 6-12 months.

The Investment Ratings are based on the expected performance of a stock (based on anticipated total return to price target) relative to the other stocks in the analyst's coverage universe (or the analyst's team coverage).\*

Rating distribution (as of October 24, 2023)	Investment Banking Relationships (as of October 24, 2023)
OUTPERFORM: 60.75%	OUTPERFORM: 4.23%
NEUTRAL: 37.38%	NEUTRAL: 1.25%
UNDERPERFORM: 1.87%	UNDERPERFORM: 0.00%

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis.

The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities.

#### **Company Specific Disclosures**

This information is subject to change at any time.

1. WS makes a market in the securities of Taiwan Semiconductor, Apple, Advanced Micro Devices Inc, Intel Corp, Microsoft and Nvidia.

#### **Price Charts**

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request.



Disclosure information regarding historical ratings and price targets is available: Research Disclosures

\*WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009.

Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

#### **OTHER DISCLOSURES**

The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request.

Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information.

#### **Retail Investors**

The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

#### **Equity Research**

CONSUMER AND RETAIL			
Beverages/Cannabis			
Gerald Pascarelli, CFA	(646) 860-7585	gerald.pascarelli@wedbush.com	
Footware & Apparel			
Tom Nikic	(212) 938-9932	tom.nikic@wedbush.com	
Hardlines Retail			
Seth Basham	(212) 938-9954	seth.basham@wedbush.com	
Restaurants			
Nick Setyan	(213) 688-4519	nick.setyan@wedbush.com	

	TMT	
Digital Media		
Michael Pachter	(213) 688-4474	michael.pachter@wedbush.com
Digital Media		
Nick McKay	(213) 688-4343	nick.mckay@wedbush.com
Entertainment/Consumer Tech		
Alicia Reese	(212) 938-9927	alicia.reese@wedbush.com
Enterprise Software		
Dan Ives	(212) 344-2073	dan.ives@wedbush.com
Hardware		
Matt Bryson	(617) 695-6302	matthew.bryson@wedbush.com
Payments/IT Services		
Moshe Katri	(212) 938-9947	moshe.katri@wedbush.com
Software		
Imtiaz Koujalgi	(212) 938-9944	imtiaz.koujalgi@wedbush.com
Internet		
Scott Devitt	(646) 604-4230	scott.devitt@wedbush.com

	HEALTHCARE	
Biotechnology		
David Nierengarten, Ph.D.	(415) 274-6862	david.nierengarten@wedbush.com
Biotechnology		
Robert Driscoll, Ph.D.	(415) 274-6863	robert.driscoll@wedbush.com
Emerging Pharmaceuticals		
Liana Moussatos, Ph.D.	(415) 263-6626	liana.moussatos@wedbush.com
Emerging Pharmaceuticals		
Andreas Argyrides	(212) 833-1399	andreas.argyrides@wedbush.com
Biotechnology		
Laura Chico, Ph.D.	(212) 668-9868	laura.chico@wedbush.com

FINANCIAL INSTITUTIONS GROUP			
Mid-Cap Banks/Disruptive Fina	ance		
David Chiaverini, CFA	(212) 938-9934	david.chiaverini@wedbush.com	
Specialty Finance			
Henry Coffey, CFA	(212) 833-1382	henry.coffey@wedbush.com	
Housing/Building Products			
Jay McCanless	(212) 833-1381	jay.mccanless@wedbush.com	
REITs			
Richard Anderson	(212) 931-7001	richard.anderson@wedbush.com	
REITS			
Jay Kornreith	(212) 938-9942	jay.kornreith@wedbush.com	

## RESEARCH MANAGEMENT

Kevin Merritt, CFA Director of Research kevin.merritt@wedbush.com (212) 938-9949

Kirsten Fraunces EVP, Head of Capital Markets kirsten.fraunces@wedbush.com (213) 688-4404

#### COMMODITY AGRICULTURE RESEARCH

#### Al Kluis

Kluis Commodity Advisors

in fo@klu is commodity advisors.com

(888) 345-2855

## FIXED INCOME FUTURE & RATES RESEARCH

#### **Arthur Bass**

Managing Director

Arthur.Bass@Wedbush.com

(212) 259-6582

# CORPORATE ACCESS

Avishai Kantor

Vice President, Corporate Access

Avishai.Kantor@wedbush.com

(212) 259-6589

Sophia Dao

Associate, Corporate Access

Sophia.Dao@wedbush.com (213) 688-4380

TRADING					
Consumer/Financials/TMT			TMT		
Bryan Lonsinger	(212) 938-9925	bryan.lonsinger@wedbush.com	Matthew Croglio	(212) 931-7071	matthew.croglio@wedbush.com
Healthcare/TMT					
Sahak Manualian	(213) 688-4533	sahak.manuelian@wedbush.com			

WEDBUSH OFFICES

Los Angeles 1000 Wilshire Boulevard Los Angeles, CA 90017 (213) 688-8000

New York 142 W 57th Street New York, NY 10019 (212) 938-9920

San Francisco 600 Montgomery Street San Francisco, CA 94111 (415) 273-7300

Chicago

141 W. Jackson Boulevard, Suite 1710A Chicago, IL 60604 (312) 786-1930